Gregory Dean A., director at Cerus Corp (NASDAQ: ), recently acquired additional shares of the company’s common stock. According to a recent filing with the SEC, Dean bought 1,725 shares at a price of $1.70 per share, for a total investment of $2,932. The buying comes as the stock trades near its own InvestingPro Fair value, with the company showing strong revenue growth of ~15% over the last twelve months. This transaction increases his total holding to 61,725 shares, reflecting his continued commitment to the company. While the stock is down ~27% over the past year, Cerus maintains a healthy balance sheet with a current ratio of 2.59. InvestingPro subscribers can access detailed insider trading analysis and comprehensive financial health indicators in the Pro Research Report, available for more than 1,400 US stocks.
In other recent news, Cerus Corporation reported strong third-quarter revenue growth of 16% to $46 million, driven largely by its North American platelet business. The company also revised its full-year product revenue guidance upward, driven by positive trends in the INTERCEPT Fibrinogen Complex (IFC) business and increased production capacity. Additionally, Cerus secured a $248 million contract with BARDA to advance the INTERCEPT Red Blood Cell program, addressing public health issues related to the safety of the blood supply.
In addition, Cerus Corporation recently announced the extension of its supply and production agreement with Porex Corporation, called the “2025 Agreement.” This contract extension aims to ensure the continued supply of key components for Cerus products, which is a strategic move for the stability of the company’s supply chain. The specifics of prices and financial conditions were not published in the press release.
In the same vein, Cerus Corporation plans to launch an LED illuminator in Europe in 2025 and in the US in 2026. Growth is expected due to new customer acquisitions and increased usage among existing customers. These are among the recent developments for Cerus Corporation.
This article was generated with the help of AI and reviewed by an editor. See our T&C for more information.
